laromestrocel (LOMECEL-B®) — Topline data
Q3 2026
Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months.Source filing
LGVN biotech catalysts & pipeline
LONGEVERON INC · Data as of 2026-09-08
Upcoming catalysts
laromestrocel (LOMECEL-B®) — Topline data
Sep 2026
Topline results from the Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct therapy for HLHS are anticipated in September 2026.Source filing
Hypoplastic Left Heart Syndrome — Topline data
2027
The Company currently anticipates a potential BLA filing with the FDA in 2027 if the current ELPIS II trial in HLHS is successful.Source filing
laromestrocel (LOMECEL-B®) — NDA/BLA submission
2027
If the current ELPIS II trial in HLHS is successful, we believe the timing would be optimal to seek a potential BLA filing with the FDA in 2027 and commercialization partner.Source filing